FindTrial
Sign In

Study on quantitative Detection of ILC2 and NETosis in Peripheral Blood of Breast Cancer patients

Polarization of ILC2 and NETosis in breast cancer patients' peripheral blood caused tumor progression by the effective of Immunosuppressive microenvironment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014575
Enrollment
Unknown
Registered
2018-01-22
Start date
2018-01-19
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

4 cohorts:none

Sponsors

TThe Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed breast cancer; 2. Clinical symptoms and signs of breast cancer; 3. All patients' clinical and pathological biopsies were in accordance with the diagnostic criteria for cancer; 4. The peripheral blood samples were collected without any clinical treatment; 5. Blood routine examination showed normal neutrophils.

Exclusion criteria

Exclusion criteria: 1. History of allergy (including allergic respiratory diseases); 2. Patients with inflammatory bowel disease, autoimmune dermatopathy, hypertension, diabetes, thyroid disease, thrombotic disease; 3. Patients with pathogenic microbial infectious diseases; 4. Long-term use of immunoregulatory drugs, immunosuppressants; 5. Patients with abnormal neutrophils or with hypergranulocyte colony stimulating factor.

Design outcomes

Primary

MeasureTime frame
ILC2;NETosi;—

Secondary

MeasureTime frame
GATA3;IL-33;IL-13;IL-5;IL-10;IL-13;RORa;dsDNA;DNA-Histone complex;NE;—

Countries

China

Contacts

Public ContactXu Yong

TThe Affiliated Hospital of Southwest Medical University

xywyll@aliyun.com+86 13980255895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026